Every Form 4 that CryoPort, Inc. (CYRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CYRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYRX filings page.
Cryoport, Inc. director and President/CEO Jerrell Shelton reported selling 28,800 shares of common stock on August 11, 2026 at a weighted average price of $14.9092 per share. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on May 11, 2026 and terminated on August 11, 2026. Following this transaction, Shelton directly held 1,201,814 shares of Cryoport common stock.
Cryoport, Inc.’s Chief Digital and Tech Officer, Edward J. Zecchini, reported a paired option exercise and share sale over two days. He exercised stock options covering 35,000 shares of common stock at an exercise price of $4.80 per share and sold 35,000 shares of common stock in open-market transactions.
The sales occurred at weighted average prices of about $15.23 on June 10, 2026 and $14.47 on June 11, 2026, with trades executed in narrow price ranges as disclosed. Following these transactions, he directly holds 109,719 shares of Cryoport common stock, and the option position referenced in this filing has been fully exercised.
Cryoport, Inc. director Linda Baddour received new equity compensation on June 5, 2026. She was granted 10,350 restricted stock rights that vest in full on June 5, 2027 and will convert into 10,350 shares of common stock on a one-for-one basis at that time.
She also received options to buy 16,077 shares of common stock at an exercise price of $15.70 per share. One-twelfth of these options vest on the 5th of each month for twelve months beginning July 5, 2026, and they expire on June 5, 2033. Following the restricted stock grant, she directly holds 68,099 common shares.
Cryoport, Inc. Chief Financial Officer Robert Stefanovich reported an open-market sale of 169,427 shares of Cryoport common stock. The sale occurred on June 4, 2026 at a weighted average price of $16.2724 per share, with individual sale prices ranging from $16.05 to $16.70. Following this transaction, Stefanovich directly owns 109,850 Cryoport common shares.
Cryoport, Inc. director Daniel M. Hancock reported equity awards consisting of restricted stock and stock options. He received 10,350 restricted stock rights that vest in full on June 5, 2027 and will convert into the same number of common shares when vested.
He was also granted options to buy 16,077 shares of common stock at an exercise price of $15.70 per share, expiring on June 5, 2033. One-twelfth of these options vest monthly on the 5th, starting July 5, 2026. Following the grants, he directly holds 69,052 common shares.
Cryoport, Inc. director Robert J. Hariri reported equity compensation awards. He received 10,350 restricted stock rights that vest in full on June 5, 2027 and then convert one-for-one into common shares.
He was also granted options for 16,077 shares of common stock at an exercise price of $15.70 per share, expiring on June 5, 2033, with 1/12 of the options vesting monthly beginning July 5, 2026. Following these awards, he directly holds 61,625 shares of common stock, plus the new option grant.
Cryoport, Inc. director Ramkumar Mandalam reported a mix of equity grants and a stock sale. On June 5, 2026, he received 10,350 restricted stock rights that vest in full on June 5, 2027 and convert one-for-one into common shares, plus options for 16,077 shares at an exercise price of $15.70 expiring in 2033.
On June 8, 2026, he executed an open-market sale of 23,214 common shares at a weighted average price of $15.4412 per share, in multiple trades between $15.40 and $15.48. Following the sale, he directly holds 67,894 common shares.
Cryoport, Inc. President and CEO Jerrell Shelton exercised stock options to acquire 104,007 shares of common stock at $1.87 per share. These options, which vested monthly over four years beginning May 6, 2016, were fully exercised, leaving 0 options from this grant. After the transaction, Shelton directly holds 1,230,614 common shares, indicating an exercise-and-hold pattern with no same-day share sales reported.
Cryoport, Inc. President and CEO Jerrell Shelton exercised stock options and increased his direct share ownership. On the transaction date, he exercised options to purchase 50,000 shares of common stock at an exercise price of $1.87 per share, receiving 50,000 common shares.
Following the transactions, Shelton directly held 1,126,607 shares of Cryoport common stock and 104,007 options to purchase common stock. The exercised options were part of a grant that vested in equal 1/48 installments each month over forty-eight months beginning on May 6, 2016, with the options expiring on May 6, 2026.
Cryoport, Inc. Chief Financial Officer Robert Stefanovich reported a small, tax-related share sale. On this Form 4, he sold 1,094 shares of common stock at $8.18 per share, with a footnote stating the shares were required to be sold under company policy to pay taxes due upon the vesting of restricted stock rights. After the transaction, he directly holds 279,277 shares, indicating this was a routine withholding event tied to equity compensation rather than a discretionary reduction of his overall stake.
Cryoport, Inc. President and CEO Jerrell Shelton exercised stock options and completed a small share sale. He exercised options to acquire 25,000 shares of common stock at an exercise price of $1.87 per share. On the same date, he sold 2,894 shares of common stock at $8.18 per share.
According to the disclosure, the sold shares were required to be sold under company policies to pay taxes due upon the vesting of restricted stock rights, making this a tax-driven, rather than discretionary, sale. After these transactions, Shelton directly owned 1,076,607 shares of Cryoport common stock.
Cryoport, Inc. Chief Scientific Officer Mark W. Sawicki reported an automatic sale of 1,341 shares of common stock at $8.18 per share. According to the disclosure, the shares were required to be sold under company policies to pay taxes due upon the vesting of restricted stock rights. Following this transaction, Sawicki directly holds 102,356 shares of Cryoport common stock.
Cryoport, Inc. officer Edward J. Zecchini reported routine equity compensation activity and a small share sale. He received 21,322 shares of Common Stock as restricted stock rights that vest in four equal annual installments beginning March 14, 2027, and a stock option grant for 63,965 shares at an exercise price of $8.60 per share expiring in 2033. On March 16, 2026, he sold 2,014 shares of Common Stock at $8.00 per share, with a footnote explaining the shares were required to be sold to pay taxes due on the vesting of restricted stock rights. After these transactions, he directly holds 109,719 shares of Common Stock.
Cryoport, Inc. President and CEO Jerrell Shelton reported two transactions. He sold 7,918 shares of Common Stock at $8.00 per share on March 16, 2026, with a footnote stating the shares were required to be sold to pay taxes due on vesting of restricted stock rights. After this tax-related sale, he directly owned 1,054,501 Common shares. On March 14, 2026, he also received a grant of 492,901 stock options with an exercise price of $8.60 per share, expiring on March 14, 2033; 1/48 of these options vest on the 14th of each month over 48 months beginning April 14, 2026.
Cryoport, Inc. Chief Scientific Officer Mark W. Sawicki reported a mix of equity awards and a small sale of common stock. He received 22,845 shares of common stock as restricted stock rights that vest in four equal annual installments beginning on March 14, 2027. He was also granted stock options for 68,534 shares at an exercise price of $8.60 per share, vesting 1/48 each month starting April 14, 2026, through forty-eight months.
On March 16, 2026, Sawicki sold 3,235 shares of common stock at $8.00 per share, which the company notes were required to be sold to pay taxes due upon vesting of restricted stock rights. After this tax-related sale, he directly holds 103,697 shares of Cryoport common stock, along with the newly granted stock options.
Cryoport, Inc. Chief Financial Officer Robert Stefanovich reported a mix of equity compensation grants, option exercises, and tax-driven share sales. He exercised options for 87,188 shares of Common Stock at $1.87 per share and sold 38,700 shares on the same day at a weighted average price of $7.7619. According to the footnotes, the sale proceeds were used to pay the option exercise price and related withholding taxes, making this largely a liquidity and tax event rather than a pure discretionary sale.
On a later date, he sold an additional 2,743 shares at $8.00 per share, which the company’s policies required to cover taxes due on vesting restricted stock rights. He also received 27,413 restricted stock rights that will vest in four equal annual installments beginning March 14, 2027, and a stock option grant for 82,240 shares at an exercise price of $8.60 per share, expiring in 2033. After these transactions, Stefanovich directly holds 280,371 shares of Cryoport common stock, so the 41,443 shares sold represent a minority portion of his overall equity position.